PARP inhibitorPhase 3 trialInvestigational
Lynparza (Olaparib)
Generic name: olaparib
How it works
Blocks an enzyme that helps repair DNA damage, making cancer cells more susceptible to death.
Cancer types
Ovarian Cancer— BRCA1/2-mutated
Efficacy
Lynparza has been shown to improve progression-free survival and response rates in BRCA1/2-mutated ovarian cancer patients.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Shows Promise for Lung Cancer Patients | Lung Cancer | phase-2 | The combination regimen demonstrated an objective response rate of 73.3% and a median overall survival of 14.6 months. | Source → |
| Olaparib Before Surgery for Newly Diagnosed BRCA-Mutant Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Olaparib Treatment in Japanese Men with Advanced Prostate Cancer | Prostate Cancer | observational | One-year overall survival rate was 80.6%, with a median overall survival of 18.4 months, and 1-year progression-free survival rate was 27.2% with a median progression-free survival of 7.6 months. | Source → |
| Testing Combination Therapy for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Olaparib plus bevacizumab may be cost-effective for ovarian cancer patients in China | Ovarian Cancer | phase-3 | — | Source → |
| Olaparib + Abiraterone for Metastatic Prostate Cancer: Real-World Study | Prostate Cancer | preclinical | — | Source → |
| Testing Adavosertib and Olaparib for Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Olaparib Before Prostate Cancer Surgery | Prostate Cancer | phase-2 | — | Source → |
| Testing Olaparib and Durvalumab in HER2 Negative BRCAm Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Olaparib Before Surgery and Chemotherapy for Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Evaluating Combination Therapies for Metastatic Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Combining Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Evaluating a Combination Therapy for Ovarian and Related Cancers | Ovarian Cancer | phase-2 | — | Source → |
| Testing Cirtuvivint and Olaparib in Platinum Resistant Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing Olaparib and Atezolizumab in BRCA Mutant Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | phase-2 | The 1-year radiographic progression-free survival rate was 77.7% (95% CI: 63.4-95.3%). | Source → |
| New Compound Disrupts Cancer Gene Expression | Colorectal Cancer | lab-study | — | Source → |
| Olaparib and Pembrolizumab in Breast Cancer Treatment | Breast Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Studying Olaparib in Metastatic Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Testing Olaparib with Radium-223 in Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Olaparib Study for Patients Who Have Completed Previous Oncology Trials | Breast Cancer | phase-3 | — | Source → |
| Testing Ceralasertib in Combination with Other Treatments for Various Cancers | Prostate Cancer | phase-2 | — | Source → |
| Cediranib and Olaparib Combination Therapy for Advanced Solid Tumors | Breast Cancer | phase-2 | — | Source → |
| Testing Cediranib and Olaparib in Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing a Combination of Two Drugs for Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Cediranib and Olaparib in Ovarian and Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Testing New Treatments for Women with Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Testing FPI-2265 and Olaparib for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Prostate Cancer Patient Shows Long-Term Response to New Treatment | Prostate Cancer | observational | To date, his PSA level has remained below 0.001 ng/ml. | Source → |
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Evaluating Olaparib in Chinese Patients with Advanced Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Testing Olaparib and Pembrolizumab for Advanced Uveal Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Combining two treatments for advanced prostate cancer | Prostate Cancer | phase-2 | Median radiographic progression-free survival was 5.0 months, and median overall survival was 19.1 months. | Source → |
| Testing Olaparib for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| Olaparib for Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Leukemia | phase-2 | — | Source → |
| Olaparib and Cediranib Combination in Ovarian Cancer Treatment | Ovarian Cancer | meta-analysis | The combination significantly prolonged progression-free survival (PFS) (overall HR = 0.78; 95% CI: 0.68-0.89; < 0.001). | Source → |
| Rare Cancer Treated with Targeted Therapy | Lung Cancer | observational | — | Source → |
| Researchers Identify New Target to Enhance Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Curcumin Analogue and Olaparib Combination Shows Promise in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| New Combination Therapy Shows Promise in Treating Triple-Negative Breast Cancer | Breast Cancer | lab-study | The combination of Olaparib and Exemestane was able to achieve enhanced tumor growth inhibition in a murine xenograft model, greater than either drug employed as a single agent. | Source → |
| TTK protein linked to resistance in ovarian cancer treatment | Ovarian Cancer | lab-study | — | Source → |
| Olaparib plus bevacizumab in older ovarian cancer patients: manageable safety and quality of life | Ovarian Cancer | phase-3 | Two years after randomization, mean Global Health Status and cognitive functioning seemed better with olaparib than bevacizumab alone (adjusted mean difference: +4.47 points and +4.82 points, respectively). | Source → |
| Combining Cancer Treatments May Help Prostate Cancer Patients | Prostate Cancer | lab-study | — | Source → |
| Combining Cancer Drugs Boosts Immune Response in Resistant Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Options for Treating Advanced Breast Cancer | Breast Cancer | review | — | Source → |
| Olaparib Monotherapy Shows Promise in Lung Cancer Treatment | Lung Cancer | meta-analysis | Olaparib monotherapy increased progression-free survival (PFS) level [ES= 7.76; 95% CI= 0.16 to 1.36; P=0.208]. | Source → |
| DRG2 levels predict response to PARP inhibitors in prostate cancer cells | Prostate Cancer | lab-study | — | Source → |
| Olaparib Therapy Side Effects in UAE Patients | Breast Cancer | observational | — | Source → |
| Olaparib vs Nonplatinum Chemotherapy in Ovarian Cancer | Ovarian Cancer | phase-3 | Overall survival with olaparib was similar to chemotherapy (median 34.9 and 32.9 months, respectively). | Source → |
| Combining drugs may improve ovarian cancer treatment | Ovarian Cancer | lab-study | The combined treatment allows a substantial dose reduction of olaparib rendering a strong synergistic effect. | Source → |
| Olaparib Maintenance Therapy Shows Promise in Ovarian Cancer | Ovarian Cancer | observational | The 1-year progression-free survival rate was 75.2% (95% CI, 63.4 to 89.2), and the median PFS was 21.0 months (95% CI, 13.8 to 28.2). | Source → |
| Combining Cancer Drugs May Improve Treatment for Advanced Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Rare Lung Disease Linked to Cancer Treatment | Breast Cancer | observational | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | review | — | Source → |
| gBRCA Testing and Olaparib in Pancreatic Cancer | Pancreatic Cancer | observational | The best responses to platinum-based chemotherapy included a complete response in one patient (12.5%) and a partial response in seven patients (87.5%). | Source → |
| Combination Cediranib and Olaparib Shows Activity in Ovarian Cancer | Ovarian Cancer | phase-2 | In platinum-sensitive ovarian cancer, the overall response rate was 77.1% and median progression-free survival was 16.4 months. | Source → |
| Olaparib Maintenance Therapy in Ovarian Cancer: Biomarker Analysis | Ovarian Cancer | phase-3 | HRD-positive patients displayed greater median PFS [17.9 months (95% CI: 14.5-22.1)] than HRD-negative patients [9.2 months (95% CI: 7.5-13.8)]. | Source → |
| Olaparib Maintenance Therapy for Ovarian Cancer: A Study at Kurume University Hospital | Ovarian Cancer | observational | The median progression-free survival was 8.9 months, and the median overall survival was 27.1 months. | Source → |
| Pancreatic Cancer Treatment Shows Promise in Rare Genetic Case | Ovarian Cancer | observational | — | Source → |
| CRABP2 May Reduce Effectiveness of Cancer Treatment Olaparib | Ovarian Cancer | lab-study | — | Source → |
| Inhibiting FSP1 Enhances Olaparib Sensitivity in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Olaparib and Niraparib Maintenance Treatments for Ovarian Cancer | Ovarian Cancer | phase-2 | The median progression-free survival of 117 patients was 20.1 months. | Source → |
| Combining Olaparib and CDK12-IN-3 to Treat Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Researchers Identify Possible Cause of Cancer Treatment Resistance | Pancreatic Cancer | lab-study | — | Source → |
| New Treatment Combination for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median radiographic progression-free survival was 25 months for olaparib plus abiraterone versus 17 months for placebo plus abiraterone. | Source → |
| Combining drugs may help overcome resistance to ovarian cancer treatment | Ovarian Cancer | lab-study | — | Source → |
| Measuring PARP Inhibitors in Ovarian Cancer Patients | Ovarian Cancer | lab-study | — | Source → |
| Olaparib Therapy in Ovarian Cancer: New Predictor Identified | Ovarian Cancer | phase-2 | The median progression-free survival was 12 months. | Source → |
| PARP Inhibitors May Work Better in Prostate Cancer When Combined with Other Treatment | Prostate Cancer | lab-study | — | Source → |
| Olaparib plus Bevacizumab May Be Cost-Effective for Advanced Ovarian Cancer Patients | Ovarian Cancer | phase-3 | — | Source → |
| Combining Two Cancer Drugs Shows Promise in Resistant Ovarian Cancer | Ovarian Cancer | phase-2 | The objective response rate was 50% (95% confidence interval, 0.15-0.72). | Source → |
| Predicting Breast Cancer Response to Olaparib with Mathematical Models | Breast Cancer | lab-study | — | Source → |
| Olaparib Monotherapy for Ovarian Cancer: Factors Affecting Survival | Ovarian Cancer | observational | — | Source → |
| Olaparib Maintenance Therapy for Ovarian Cancer Patients | Ovarian Cancer | observational | Among patients with partial remission from most recent chemotherapy, 3 (3.84%) showed complete response and 6 (7.69%) showed partial response. | Source → |
| Olaparib Can Be Re-Administered After Chemotherapy | Breast Cancer | observational | — | Source → |
| Olaparib Use in Ovarian Cancer Patients with End-Stage Renal Disease | Ovarian Cancer | lab-study | This maintenance therapy led to 16 months of progression free survival. | Source → |
| Olaparib Extends Life Without Symptoms for Pancreatic Cancer Patients | Pancreatic Cancer | phase-3 | TWiST was significantly longer for olaparib than placebo in the base-case analysis (14.6 vs 7.1 months; 95% CI, 2.9-12.0; p = .001) | Source → |
| Olaparib Efficacy in Relapsed Ovarian Cancer Patients | Ovarian Cancer | observational | The median progression-free survival was 17.0 months. | Source → |
| mA reader HNRNPA2B1's role in breast cancer cell growth and response to treatment | Breast Cancer | lab-study | Downregulation of HNRNPA2B1 partially reversed de novo resistance to olaparib in breast cancer. | Source → |
| Choosing the Right Maintenance Therapy for Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Combining Olaparib and Radiotherapy for Triple-Negative Breast Cancer | Breast Cancer | phase-1 | Three-year overall survival was 83% (95% CI, 70%-100%) and event-free survival was 65% (95% CI, 48%-88%). | Source → |
| Olaparib and Bevacizumab Benefit High-Grade Ovarian Cancer Patients with BRCA Mutations | Ovarian Cancer | phase-3 | The 24-month PFS rate was estimated to be 89% and 15% for patients with BRCA1m located in the DBD, with a hazard ratio of 0.08 (olaparib + bevacizumab versus placebo + bevacizumab). | Source → |
| Olaparib treatment in pancreatic cancer patients with BRCA2 mutation | Pancreatic Cancer | observational | The patient remained 10 months on olaparib treatment, without disease progression. | Source → |
| Combining Olaparib and Arsenic Trioxide May Help Treat Platinum-Resistant Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Desensitization Method for Allergic Reactions to Cancer Drug Olaparib | Ovarian Cancer | lab-study | — | Source → |
| Combining Cancer Drugs May Improve Ovarian Cancer Treatment | Ovarian Cancer | lab-study | The combination index (CI) values partially show synergisms in combinations at 100 nM and 500 nM P8-D6. | Source → |
| Olaparib Shows Promise in Asian Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | Radiographic progression-free survival (rPFS) favored olaparib versus control in Cohort A [rPFS 7.2 vs. 4.5 months, HR 0.58, 95% CI 0.29-1.21]. | Source → |
| Combining Oleanolic Acid and Olaparib Enhances Radiotherapy in Triple Negative Breast Cancer | Breast Cancer | lab-study | The sensitization enhancement ratios (SER) were 1.16-1.65. | Source → |
| Rare skin side effect reported in patient taking olaparib for ovarian cancer | Ovarian Cancer | observational | — | Source → |
| PARP Inhibitor Use in Gynecological Cancer Patients Compared | Ovarian Cancer | observational | — | Source → |
| Tumor Genomic Testing for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Olaparib Maintenance Treatment for Ovarian Cancer in Chinese Patients | Ovarian Cancer | phase-3 | Olaparib treatment led to an improvement in progression-free survival compared with placebo (hazard ratio = 0.44, 95% confidence interval: 0.17-1.19; median = 13.8 vs. 5.5 months). | Source → |
| Olaparib's Safety for Ovarian Cancer Treatment | Ovarian Cancer | review | — | Source → |
| Olaparib Monotherapy Shows Promise in Advanced Pancreatic Cancer | Pancreatic Cancer | observational | — | Source → |
| Olaparib Maintenance Therapy for Ovarian Cancer Patients | Ovarian Cancer | phase-3 | Median progression-free survival was 9.2 months (95% confidence interval [CI], 7.6-10.9) in the overall population. | Source → |
| New Compound Sensitizes Ovarian Cancer to Treatment | Ovarian Cancer | lab-study | — | Source → |
| Olaparib and Bevacizumab Combination Extends Progression-Free Survival in Ovarian Cancer | Ovarian Cancer | phase-3 | Olaparib plus bevacizumab provided a substantial PFS benefit versus bevacizumab alone in the homologous recombination deficiency (HRD)-positive subgroup, with a 61% reduction of risk of progression or death in the higher-risk group and an 85% reduction in the lower-risk group. | Source → |
| Combining two drugs may slow pancreatic cancer growth | Pancreatic Cancer | lab-study | — | Source → |
| Combining two cancer drugs may improve treatment for ovarian cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining Cancer Drugs May Improve Treatment for Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining Two Drugs Shows Promise in Treating Ovarian Cancer | Ovarian Cancer | animal-study | The combination yielded significantly lower tumor weight and fewer tumor nodules compared with the control group (< 0.04 and < 0.03 in the A2780luc ip1 mouse model, and = 0.006 and = 0.059 in the OVCAR5 mouse model). | Source → |
| Olaparib Extends Survival in Some Breast Cancer Patients | Breast Cancer | phase-3 | The 3-year invasive disease-free survival was 85.9% in the olaparib group and 77.1% in the placebo group. | Source → |
| Olaparib Monotherapy Effective in Some Breast Cancer Patients | Breast Cancer | phase-3 | The median investigator-assessed progression-free survival was 8.11 months. | Source → |
| Olaparib Treatment for Ovarian Cancer: A Case Study | Ovarian Cancer | observational | — | Source → |
| New Uses for PARP Inhibitors in Ovarian Cancer Treatment | Ovarian Cancer | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.